Heart Failure Latest News Archive
The use of both NSAID and aspirin was positively associated with incident HF in adults with no prior history of CVD.
There have been over 75 medical device reports of the cardiac assist Maquet/Datascope IABP devices shutting down while running on battery.
The US Hospital Readmissions Reduction Program (HRRP) has successfully reduced readmission rates for certain conditions.
Investigators sought to determine the incidence of cardiac decompensation during pregnancy in cancer survivors.
A diagnosis of cardiovascular disease or presence of related biomarkers, as well as the use of antirheumatic drugs may be associated with a higher risk for heart failure in patients with rheumatoid arthritis.
LVEF values measured with 3DE were stronger predictors of major arrhythmic events than the same values calculated with 2DE.
The Company expects to start Phase 3 studies for ATTR cardiomyopathy and polyneuropathy in the first half of 2019.
Patients currently or recently hospitalized for heart failure undergoing initial ICD placement experienced a higher rate of composite periprocedural complications compared with those without a recent heart failure hospitalization.
Natriuretic peptides and high-sensitive troponin may be useful for cardiac risk stratification in acute syncope.
Older patients, women, and racial and ethnic minorities are underrepresented in the majority of heart failure (HF) clinical trials.
HbA1c levels following left ventricular assist device implantation were statistically significantly lower than before surgery.
The Company is currently enrolling patients in a randomized, double-blind, placebo-controlled Phase 2 trial; they expect to enroll 175 in total.
Rivaroxaban was not superior to placebo for reducing the rate of death, MI, or stroke in patients with chronic heart failure.
Tafamidis was associated with reduced all-cause mortality and cardiovascular-related complications in patients with transthyretin amyloid cardiomyopathy.
The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.
Investigators examined the excess risk for heart failure in patients with type 2 diabetes and compared the risk with that in the general population without diabetes.
To date, there have been no reports of any adverse events related to this recall.
After 2.1 years of follow-up, 49% of patients who had emphysema on chest CT were readmitted for heart failure and 24% had died.
The Phase 4, randomized, open-label, parallel-group TRANSITION study (N=1002) evaluated the safety and tolerability of Entresto in HFrEF patients after they were stabilized following an acute heart failure episode when treatment was initiated either pre-discharge or post-discharge.
GutHeart, a new ongoing clinical trial, will investigate the potential benefits of treating gut bacteria in heart failure.
The most common findings in patients with Chagas cardiomyopathy include cardiac rhythm abnormalities, myocardial abnormalities, aneurysms, and thromboembolism.
The FDA has approved Galafold for the treatment of adults with a confirmed diagnosis of Fabry disease.
For patients unable to swallow an intact capsule, the pellets can be sprinkled over soft food (eg, applesauce, yogurt, pudding) or given via a nasogastric (NG) tube.
There is a paucity of data regarding the cardiotoxicity and the monitoring adherence habits of patients undergoing treatment with trastuzumab or anthracyclines, commonly used therapies among patients with HER2-positive breast cancer.
For this study, researchers searched multiple databases for studies in which the effectiveness of various pharmacologic interventions were evaluated in patients with HFrEF.
HCV viral eradication resulted in improved left ventricular diastolic dysfunction.
Canagliflozin vs other SGLT2 inhibitors and non-SLGT2 inhibitors were examined for the risk for heart failure-related hospitalization and below the knee amputation.
As valsartan is used to treat various cardiovascular conditions including heart failure and hypertension, patients should continue to take their medications until they have a replacement product,
When sleep apnea was not managed with continuous positive airway pressure, the risk for heart failure increased, regardless of age.
Investigators examined the effect of intensified multifactorial intervention on the risk for heart failure-related hospitalization in patients with type 2 diabetes and microalbuminuria.
According to HF guidelines, beta-blockers must be titrated to a specific target dose in order to obtain their morbidity and mortality benefit in HF patients.
Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.
Impaired global longitudinal strain and left ventricular hypertrophy may be predictive of incident heart failure in patients with asymptomatic type 2 diabetes.
Acute myocarditis complicated by left ventricular systolic dysfunction confers a higher risk for cardiac death and heart transplant compared with uncomplicated acute myocarditis.
Neprilysin Inhibition May Reduce Renal Function Deterioration in Comorbid T2D and Chronic Heart Failure
This study aimed to examine the efficacy of neprilysin inhibition in treating renal disease in individuals with T2D.
The HeartMate 3™ Left Ventricular Assist System has been recalled because of a potential malfunction in the outflow graft assembly that may cause it to twist and close up over time.
A single-beat estimation of preload recruitable stroke work and its coupling with pulmonary arterial load in pulmonary arterial hypertension provided high accuracy for evaluating right ventricular contractility.
The American Heart Association scientific statement offers recommendations on right-sided heart failure regarding physical examination, serum markers, and imaging.
Portable sleep monitoring may accurately diagnose sleep apnea in patients who are hospitalized with heart failure.
Sacubitril/valsartan was associated with greater improvements in physical and social activities in patients with heart failure with reduced ejection fraction than enalapril.
Compared with the enalapril-treated group, those treated with sacubitril/valsartan were found to have significantly slower kidney decline (-1.3 vs -1.8mL/min/1.73m2 per year; P<0.0001).
New Class 1 recommendations involve the referral of inpatients and outpatients to cardiac rehabilitation programs that include exercise training.
The TAZPOWER study is a randomized, double-blind, placebo-controlled Phase 2/3 crossover study evaluating the safety and efficacy of elamipretide (daily subcutaneous injections) in 12 male patients (aged ≥12 years) with genetically-confirmed Barth syndrome.
Entresto may improve limitations in physical and social activities in patients with heart failure.
Although they acknowledge the preliminary data is subject to further analysis, they say it demonstrates a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months.
A recent study evaluated the effects of SGLT-2i and other glucose-lowering drugs on cardiovascular event outcomes in patients with type 2 diabetes from 6 countries in 3 world regions.
A Smartwatch band paired with an app records a 30-second single-lead rhythm strip.
Primary prevention with aspirin may reduce all-cause mortality in patients with heart failure and type 2 diabetes.
A shared decision-making program between patients with end-stage heart failure being considered for destination therapy left ventricular assist device and their caregivers was associated with improvement in patient knowledge.
Rheumatoid arthritis may be associated with an increased risk for hospitalization from heart failure.
High-sensitivity cardiac troponin is associated with incident heart failure.
Researchers discovered an association between global pulmonary vascular remodeling and pulmonary hypertension in patients with heart failure.
The American College of Cardiology released a decision pathway addressing 10 pivotal issues in heart failure with reduced ejection fraction.
Patients with chronic heart failure and diabetes may have a greater reduction in mortality with higher beta-blocker doses.
Incident heart failure hospitalizations were reduced with plant-based diets.
In addition to known risk factors, coffee consumption reduces the risk of poor outcomes in heart failure and stroke.
Researchers compared different administrations of furosemide in patients with acute decompensated heart failure.
Patients with heart failure who received transcatheter aortic valve replacements saw decrease in aortic valve mean gradient.
A study examined whether patients with heart failure with reduced ejection fraction who do not tolerate a high enalapril dose may still benefit from lower doses.
Patients who received synchronized left ventricular pacing with the AdaptivCRT had a lower risk of developing atrial fibrillation compared with patients who received conventional cardiac resynchronization therapy.
Patients with systolic heart failure see physical benefits with sacubitril/valsartan.
High-risk patients with heart failure and reduced ejection fraction did not benefit from an amino-terminal pro-B-type natriuretic peptide-guided treatment strategy compared with usual care.
Patients with type 2 diabetes who received sodium-glucose co-transporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors had a lower risk for heart failure hospitalizations.
Patients treated with zoledronic acid had a higher risk for atrial fibrillation and other arrhythmias as well as heart failure vs untreated patients.
Study finds genuine difference between a fixed-dose combination of isosorbide dinitrate plus hydralazine HCl and an off-label combination of the separate generic drugs for the treatment of heart failure in African American patients.
The FDA has approved CaroSpir, the first oral liquid formulation of spironolactone for hypertension and heart failure treatment.
Most pharmacotherapies appear not to have significant effect on all-cause or cardiovascular mortality in heart failure with preserved ejection fraction.
Researchers have used a gene-editing tool to repair the segment of DNA that causes hypertrophic cardiomyopathy.
N-terminal pro-B-type natriuretic peptide showed the strongest association with heart failure in patients with type 2 diabetes.
Greater left ventricle mass and left ventricle mass indexed to height were found in participants with a history of childhood asthma.
In patients with acute myocardial infarction without heart failure, beta-blockers did not reduce mortality risk at 1 year.
Individuals who had the lowest levels of recommended physical activity had elevated levels of high-sensitivity cardiac troponin T.
Exercise Capacity in Heart Failure With Reduced Ejection Fraction Not Improved With Iron Supplementation
Patients with heart failure with reduced ejection fraction and iron deficiency do not benefit from iron supplementation.
Patients with acute heart failure who received intravenous morphine in the emergency department had higher mortality compared with patients who did not receive morphine.
Women with fewer menstrual cycles are at a higher risk for incident heart failure.
Ivabradine did not improve exercise capacity, diastolic function, or NT-proBNP levels in patients with heart failure with preserved ejection fraction.
Direct oral anticoagulation reduced the risk of congestive heart failure admissions and all-cause mortality in both genders.
Patients with comorbid congestive heart failure who received parenteral nutrition experienced increased negative outcomes in their hospital stay.
HIV poses higher risks of heart failure even at younger ages of infection, and 25% of all new cases in the United States occur in people between age 13 and 24.
Renin-angiotensin system inhibition was linked with a reduced 3-year risk of all-cause mortality in patients with congestive heart failure and atrial fibrillation.
HbA1c decreased by 0.16% in the enalapril group vs 0.26% in the sacubitril/valsartan group.
Subclinical hypothyroidism with TSH has been linked to worse survival in patients with preexisting heart failure, according to research.
Total hip bone mineral density was associated with heart failure risk in black and non-black men, with an interaction by race.
Researchers noted that the relative risk of heart failure increased following a patient's RA diagnosis.
A decline in function status occurred an average of 2 years before hospitalization for myocardial infarction, and 3 years before heart failure and stroke.
Although more women are admitted with Takotsubo cardiomyopathy, more men ultimately die.
The Advanced Training Statement for advanced heart failure and transplant cardiology consists of 6 general competencies.
Cardiac MRI should be used to differentiate Takotsubo cardiomyopathy from similar conditions.
The association between proton pump inhibitor use and incidence of heart failure and death was recently evaluated in a study.
Patients with both heart failure and atrial fibrillation had a pattern of milder Alzheimer's pathology.
Renin-angiotensin system inhibitors reduced cardiovascular events in patients with coronary artery disease when compared with placebo but not active controls.
Patients with heart failure may benefit from influenza vaccination.
A higher dose of amiodarone after ventricular tachycardia ablation was independently associated with a shorter time to death.
Of 307 patients, only 1 patient's ICD had electromagnetic interference produced by a telephone.
Data derived from speckle-tracking echocardiography and conventional methods and data derived solely from speckle-tracking echocardiography showed a high degree of statistical overlap.
The left atrial appendage closure device was found to have excellent success and low complication rates in a post-FDA approval study.
The American Heart Association presents recommendations for managing pregnancy in women with congenital heart disease.
In older adults who received implantable cardioverter-defibrillators as secondary prevention of sudden cardiac death, the risk of death was 21.8%.
St. Jude Medical implantable cardiac devices and the Merlin@home Transmitter may be vulnerable to cybersecurity attacks.
Left ventricular depression is known to occur in patients with severe sepsis or septic shock.
The Cardiology Advisor Articles
- Cardiac Troponin Elevation Predicts Major Adverse Events Even Without Specific Diagnosis
- How Has the Medicaid Expansion Affected Patients Hospitalized With Acute MI?
- Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome
- Association Between Statins and Depression Likely Mediated by Confounding
- Occupational Metal, Pesticide Exposure May Be Associated With Increased CVD Risk
- ASH Develops Practice Guidelines for Venous Thromboembolism
- Tetralogy of Fallot: Long-Term Outcomes After Surgical Repair
- Cardiac Troponin Elevation Predicts Major Adverse Events Even Without Specific Diagnosis
- Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation in Heart Failure
- Trends in Endocarditis Incidence After Implementation of 2007 AHA Recommendations
- Researchers Identify Golden Ratio Between Pulmonary Pressure Components in PAH
- FDA: Potential Increased Mortality With Paclitaxel-Coated Balloons, Stents for PAD
- Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH
- Elevated Myocardial T1 Associated With Increased Septal Angle in PAH
- Pulmonary Hypertension Intensive Care Options Depend on Treatment Goals